CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle

Slotta C, Schlüter T, Ruiz-Perera LM, Kadhim HM, Tertel T, Henkel E, Hübner W, Greiner J, Huser T, Kaltschmidt B, Kaltschmidt C (2017)
PLOS ONE 12(8): e0182373.

Download
OA 9.74 MB
Journal Article | Original Article | Published | English
Author
; ; ; ; ; ; ; ; ; ;
Abstract
Cervical cancer is the fourth common cancer in women resulting worldwide in 266,000 deaths per year. Belonging to the carcinomas, new insights into cervical cancer biology may also have great implications for finding new treatment strategies for other kinds of epithelial cancers. Although the transcription factor NF-κB is known as a key player in tumor formation, the relevance of its particular subunits is still underestimated. Here, we applied CRISPR/Cas9n-mediated genome editing to successfully knockout the NF-κB subunit c-REL in HeLa Kyoto cells as a model system for cervical cancers. We successfully generated a homozygous deletion in the c-REL gene, which we validated using sequencing, qPCR, immunocytochemistry, western blot analysis, EMSA and analysis of off-target effects. On the functional level, we observed the deletion of c-REL to result in a significantly decreased cell proliferation in comparison to wildtype (wt) without affecting apoptosis. The impaired proliferative behavior of c-REL-/- cells was accompanied by a strongly decreased amount of the H2B protein as well as a significant delay in the prometaphase of mitosis compared to c-REL+/+ HeLa Kyoto cells. c-REL-/- cells further showed significantly decreased expression levels of c-REL target genes in comparison to wt. In accordance to our proliferation data, we observed the c-REL knockout to result in a significantly increased resistance against the chemotherapeutic agents 5-Fluoro-2’-deoxyuridine (5-FUDR) and cisplatin. In summary, our findings emphasize the importance of c-REL signaling in a cellular model of cervical cancer with direct clinical implications for the development of new treatment strategies.
Publishing Year
ISSN
Financial disclosure
Article Processing Charge funded by the Deutsche Forschungsgemeinschaft and the Open Access Publication Fund of Bielefeld University.
PUB-ID

Cite this

Slotta C, Schlüter T, Ruiz-Perera LM, et al. CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle. PLOS ONE. 2017;12(8): e0182373.
Slotta, C., Schlüter, T., Ruiz-Perera, L. M., Kadhim, H. M., Tertel, T., Henkel, E., Hübner, W., et al. (2017). CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle. PLOS ONE, 12(8), e0182373. doi:10.1371/journal.pone.0182373
Slotta, C., Schlüter, T., Ruiz-Perera, L. M., Kadhim, H. M., Tertel, T., Henkel, E., Hübner, W., Greiner, J., Huser, T., Kaltschmidt, B., et al. (2017). CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle. PLOS ONE 12:e0182373.
Slotta, C., et al., 2017. CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle. PLOS ONE, 12(8): e0182373.
C. Slotta, et al., “CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle”, PLOS ONE, vol. 12, 2017, : e0182373.
Slotta, C., Schlüter, T., Ruiz-Perera, L.M., Kadhim, H.M., Tertel, T., Henkel, E., Hübner, W., Greiner, J., Huser, T., Kaltschmidt, B., Kaltschmidt, C.: CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle. PLOS ONE. 12, : e0182373 (2017).
Slotta, Carsten, Schlüter, Thomas, Ruiz-Perera, Lucia M., Kadhim, Hussamadin M., Tertel, Tobias, Henkel, Elena, Hübner, Wolfgang, Greiner, Johannes, Huser, Thomas, Kaltschmidt, Barbara, and Kaltschmidt, Christian. “CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle”. PLOS ONE 12.8 (2017): e0182373.
All files available under the following license(s):
Copyright Statement:
This Item is protected by copyright and/or related rights. [...]
Main File(s)
File Name
Access Level
OA Open Access
Last Uploaded
2017-08-15T08:50:21Z

This data publication is cited in the following publications:
This publication cites the following data publications:

64 References

Data provided by Europe PubMed Central.

Role of ICAM1 in invasion of human breast cancer cells.
Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, Denissenko MF., Carcinogenesis 26(5), 2005
PMID: 15774488
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.
Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN, Swigart LB, Evan GI., Genes Dev. 27(5), 2013
PMID: 23475959
Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells.
Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C., Oncogene 18(4), 1999
PMID: 10023670
Good cop, bad cop: the different faces of NF-kappaB.
Perkins ND, Gilmore TD., Cell Death Differ. 13(5), 2006
PMID: 16410803

AUTHOR UNKNOWN, 0
A census of human cancer genes.
Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR., Nat. Rev. Cancer 4(3), 2004
PMID: 14993899
Cellular processing of platinum anticancer drugs.
Wang D, Lippard SJ., Nat Rev Drug Discov 4(4), 2005
PMID: 15789122
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM., Biochim. Biophys. Acta 1587(2-3), 2002
PMID: 12084461

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 28767691
PubMed | Europe PMC

Search this title in

Google Scholar